Recital 51, Decision_act (EU) 2004/104

In forcesince 27 Nov 2002

Aventis further states that "It was clear for both companies that sooner or later one of them would have to exit the market and would therefore buy its internal need of meglumine (methylglucamine) from the remaining producer at favourable terms"(29).